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ABSTRACT
The term idiopathic short stature (ISS) refers to short children with no identifiable disorder of
the growth hormone (GH)/insulin like growth factor (IGF) axis and no other endocrine, genetic
or organ system disorder. This heterogeneous group of short children without GH deficiency
(GHD) includes children with constitutional delay of growth and puberty, familial short stature,
or both, as well as those with subtle cartilage and bone dysplasias. In rare cases, ISS is due to
IGF molecular abnormalities. In this review we tackle the major challenges in the definition and
treatment of ISS.
Conflict of interest: None declared
DEFINITION
A heterogeneous population
Idiopathic short stature (ISS) is defined
as a condition characterized by a height
more than 2 standard deviations below the
corresponding average height for a given
age, sex and population, without findings
of disease.(1, 2, 3) According to this defini-
tion, it is estimated that approximately 80%
of all children referred for short stature, at
the end of the diagnostic work-up, will be
labeled as ISS.(4) The concept behind this
definition is that ISS can be considered as
part of the continuum extending from com-
plete growth hormone deficiency (GHD) to
normality and covering different degrees of
GH secretion and responsiveness. 
To better define this population, ISS has
recently been subdivided into two major
groups: a) familial short stature (FSS), when
the child is short compared with the reference
population, but remains within the range of
target height; b) non-familial short stature
(NFSS), when the child is short both in com-
parison with the reference population and the
target height. This latter subgroup inevitably
includes short children with constitutional
delay of growth and puberty (CDGP).(1)
The need of a sub-categorization stems
from the classical distinction between the
“normal variants” of growth (namely FSS
and CDGP), characterized by the achieve-
ment of an adult height within the range of
target height, and the “real” ISS children,
whose growth pattern and natural history
are different from FSS and CDGP and are
thought to have a different etiology. 
More about the distinction between
ISS and normal variants of growth
Classically, FSS children present with
stature within the target height range, no
bone age delay and normal growth rate
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use(≥25th centile), whilst CGDP subjects show
short stature, bone age delay (usually ≥2
years), delayed onset of puberty (≥13 years in
girls, ≥14 years in boys), normal growth rate
(≥25th centile), and often familial history of
delayed puberty. 
It has been objected that before the age
of 13 (for girls) or 14 (for boys) years, cer-
tainty about the timing of pubertal onset
(normal or delayed) cannot be obtained.
Before that age, a delayed bone age is
indeed to some extent predictive for CDGP,
but it is a clinical observation that some chil-
dren with delayed bone age may enter
puberty at a normal age, and vice versa.
Therefore a clear distinction between ISS
and CDGP may be difficult.(5) Nevertheless,
provided that the child fulfills the criteria for
the definition of CDGP and endocrine tests
are normal, the likelihood of CDGP is
extremely high. Moreover, typically the child
with CDGP starts losing centiles in the
growth curve around the age when puberty
usually begins in the general population. 
We believe that for the management of
the child with short stature, the auxological
sub-classification is helpful. With respect to
the diagnostic process, in a child with FSS (if
pathological causes of parental shortness are
considered unlikely) the chance of finding a
pathological disorder is low. Thus, the full
set of diagnostic investigations may not be
necessary, unless growth rate slows down,
and these children attain their genetic poten-
tial. If a child’s height SDS is lower than the
target range (NFSS) and there is a positive
family history of CDGP, the likelihood of
CDGP is high, and the experienced clinician
may follow an expectant course.
Therefore, ISS is a diagnosis that is not
based on positive findings in the diagnostic
work-up, but on exclusion of other recogniza-
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Table 1: Information to be gathered about familial and personal history. 
Medical history Interpretation
Family history
Presence of endocrine, thyroid, or  growth disorders, Possible genetic causes 
skeletal dysplasias, autoimmune diseases 
Parents’ heights To calculate target height
Tempo of parental puberty  Possible familial history of delayed puberty
Personal history
Birth length and weight, gestational age Comparison with reference data to evaluate if the child was 
born small or appropriate for gestational age 
Information about pregnancy (IUGR, drugs or infections)  All these conditions can cause growth retardation 
Information about child birth (breech delivery, prolonged All these conditions are associated to pituitary or
jaundice, asphyxia) hypothalamic dysfunctions
Information about previous diseases, operations or medication Possible organic causes of short stature
Symptoms suggestive for cardiac, pulmonary, intestinal, Possible organic causes of short stature. The easy fatigue
renal, endocrine or CNS diseases; possible easy fatigue or can be a symptom of anemia, celiac disease or renal
sleepiness diseases; sleepiness can be a sign of hypothyroidism
Nutritional status Detailed assessment of feeding pattern if there is failure to 
thrive; in adolescents possible presence of anorexia nervosa
Previous data about height and  weight  To draw a complete growth curve
Age at start of puberty (in girls: breast budding; in boys: To evaluate if the onset  of puberty is early, normal or 
testicular enlargement >4 ml) delayed
Mental retardation Possible presence of syndromes, chromosomal or
metabolic diseases
IUGR: introuterine growth retardation; CNS: central nervous systemble conditions. More specifically, children with
ISS should be considered GH sufficient, should
have normal body proportions, no history of a
low birth size (small for gestational age, SGA),
no chromosomal abnormalities, no dysmorphic
syndromes and no systemic, endocrine or
Cianfarani S., et al.
J Clin Res Ped Endo 2009;1(3):105–115 107
Table 2: Signs and symptoms to look for in the clinical examination of a child with short stature.
Physical examination Interpretation 
Measurements:
Length/Height Comparison with reference charts, evaluation of growth
pattern, child’s height comparison with target height
Weight BMI calculation: 
• if the child is underweight, suspect intestinal diseases, 
metabolic disorders, SGA;
• if the child is overweight or obese, suspect
hypothyroidism, Cushing syndrome, GH deficiency
Head circumference Dysmorphic Syndromes
Body proportions, SH/H ratio (or upper/lower segment ratio) Skeletal Dysplasias
Facies:
Dysmorphic features Primary growth plate disorders (syndromes)
Frontal bossing, depressed nasal bridge, mid-facial hypoplasia Diseases of the GH/IGF-I axis: GHD, GH resistance, IGF-I 
deficiency
Moon face, plethoric facies Cushing’s syndrome
Neck, chest, abdomen
Thyroid size and consistency Hashimoto’s thyroiditis
Hypertension Renal diseases, Cushing’s syndrome
Abdominal distension Celiac disease
Hepatomegaly, splenomegaly Chronic liver diseases, metabolic diseases
Striae Cushing’s syndrome
Virilization (Hirsutism, acne) Cushing’s syndrome
Pubertal stage Constitutional delay of growth and puberty
Micropenis Hypogonadism, hypopituitarism
Papilloedema, diplopy, visual field defects CNS pathology
CNS: central nervous system; GH: growth hormone; IGF-I: insulin like growth factor-I; GHD: GH deficiency; SH/H: sitting height/height; BMI: body
mass index.
Table 3: Laboratory tests for screening of children with short stature.
Laboratory tests Significance 
Blood
Hemoglobin Chronic anemia 
Creatinine, albumin, sodium, potassium, calcium, phosphate, Renal diseases,  rickets and malabsorption
alkaline phosphatase
IgA anti-endomysium, IgA anti-transglutaminase, total IgA Celiac disease
Free-T4, TSH Hypothyroidism
FSH, karyotype  Turner syndrome in girls
IGF-I, IGFBP-3 First screening for GH deficiency or GH resistance
Acid-base balance (0-2 years) Renal tubular acidosis
Urine
pH, glucose, proteins, blood  Renal diseases
T4: thyroxine; TSH: thyrotropin; FSH: follicle stimulating hormone; IGF-I: insulin like growth factor-I; IGFBP-3: IGF binding protein-3, GH: growth hormonenutritional diseases.(1) Finally, normal variants
of growth (FSS and CGDP) should be exclud-
ed. The completeness of the medical history
(Table 1), the accuracy of the physical exami-
nation (Table 2) and the investigations (Table
3) determine the possibility of identifying
underlying pathologies. 
The frequency of ISS amongst short
children
In short individuals the prevalence of
known growth disorders is obviously much
higher than in the total population, but these
still constitute the minority. In most short chil-
dren no diagnosis can be made, and these are
labeled as having ‘‘idiopathic short stature”.
The percentage of pathology found in most
studies is approximately 5%.(4, 6, 7) Whereas
in 15% a history of a low birth weight or length
for gestational age (SGA) is found.(8) This
means that in approximately 80% of the short
children presented to a pediatric clinic there is
no history of a low birth weight and/or length,
and no pathology can be detected. The vast
majority of them have normal variants of
growth (FSS or CDGP) and will attain an adult
height within the target height range. 
Short stature: a statistical concept or
a disease?
Shortness is defined as a condition in
which the height of the individual is 2 SD
below the corresponding mean height for a
given age, sex and population group.
1
Therefore, short stature is defined on the basis
of a statistical cut-off point which does not
automatically imply the presence of an under-
lying pathology. Height distributes in a definite
population according to a Gaussian curve in
which subjects with a height <-2 SD can either
be considered as the necessary 2.3% shortest
part of the normal distribution, or as individu-
als with a disorder that restricts growth.(5)
Pathophysiology of  ISS
ISS children represent a highly heteroge-
neous population with multiple potential
pathophysiological mechanisms.(9)
In the diagnostic work-up for ISS, dys-
morphic syndromes must be excluded, but it
is not agreed how far genetic testing should
go before the condition can be labeled as
idiopathic. For example, there is wide agree-
ment that all girls should be tested for Turner
syndrome, but there is no consensus of
whether all short children should be tested
for a heterozygous deletion or mutation of
SHOX, which has been described in about
2.5% of ISS children.(10) Recently a clinical
score was developed to predict the likeli-
hood of a SHOX defect and this can be used
for improved selection of patients for test-
ing.(11) There is no agreement on either
what skeletal dysplasias should be excluded
or what cut-off limit with respect to body
proportions should be used. To assess body
proportion, in Europe the sitting
height/height (SH/H) ratio and in the United
States the upper/lower segment ratio is used,
but both of these ratios are strongly influ-
enced by secular trend and reliable refer-
ences are not available. 
By definition, children with ISS have nor-
mal GH secretion, which is almost always
investigated by a pharmacological GH provo-
cation test. Theoretically, they could have
reduced spontaneous 24-hr GH secretion.
However, the assessment of spontaneous GH
secretion is very rarely included in the clinical
evaluation of short stature and the entity of
GH neurosecretory dysfunction (12) still
remains controversial. Some ISS children have
been found to have low concentrations of
growth hormone binding protein (GHBP),
suggesting reduced GH receptor (GHR) func-
tion.(13) These patients tend to have lower
IGF-I levels yet higher endogenous GH secre-
tion, suggestive of partial GH insensitivity
(GHI).(14) An overlap exists between ISS
patients and those with partial or atypical
GHI. This was appreciated from the study of
the European cohort of GHI patients, (15)
some of whom did not have the typical
appearance of Laron syndrome. In fact, some
had milder short stature and normal facial
appearance with less biochemical abnormali-
Idiopathic Short Stature
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that the vast majority of ISS children have IGF-
I in the low normal range and normal GH
concentrations. Our preliminary data, collect-
ed from a group of 94 children (subdivided in
NFSS, FSS and controls), show a significant
difference in mean serum IGF-I SDS concen-
trations between NFSS children and controls
(Figure 1). The existence of a mild form of
GHI is hence extremely rare in ISS population. 
Defects in post-receptor GH signaling
have been described.(17, 18, 19) A homozy-
gous mutation in exon 15 of the STAT5b gene
has been reported. The mutant protein could
not be activated by GH, therefore failing to
activate gene transcription.(18) However, the
first reported case showed a complex pheno-
type characterized by features of severe GHI
together with immunodeficiency consistent
with a non-functional STAT5b.
In summary, some children labeled as ISS
may have a low spontaneous GH secretion
that has not been detected, a genetic disorder
that has not been studied (e.g. SHOX hap-
loinsufficiency), a dysfunctional GH promot-
er or an abnormal GH molecule that has not
been analyzed, or some form of decreased
responsiveness to GH by a genetic defect in
GH signaling. It is likely that in the coming
years more identifiable clinical conditions will
be discovered that nowadays are still resting
under the cover of the term ‘‘idiopathic”.
THERAPY
GH 
A careful review of the diagnostic
approach to short stature over the last 50
years would inevitably lead to the conclusion
that rather than diagnosis dictating therapy,
the availability of GH dictated diagnosis.
Since recombinant GH has become widely
available (1985), its indications are substan-
tially increased. The treatment with GH for
ISS has been approved by the Food and Drug
Administration (FDA) in United States in July
2003 for children shorter than -2.25 SDS (1.2
percentile). Very few studies report on the
efficacy and safety of long-term GH treatment
of ISS children until the achievement on adult
height, and, for this reason, in Europe this
indication has not yet been approved. 
According to the “Consensus guidelines
for the diagnosis and treatment of children
with ISS” this treatment should be considered
if the height ranges from -2 SDS to -3 SDS and
the optimal age to initiate treatment is 5 years
to early puberty.(20) The therapy should gen-
erally not be started before the age of four
and it should be prescribed until the growth
is complete (i.e. growth rate less than 1-2
cm/years, and/or bone age over 16 years in
boys and 14 years in girls).(2, 20) Alternatively
the treatment could be discontinued when
child’s height achieves the normal adult range
(over -2 SDS). It is important to consider
adverse effects, cost of therapy, patients’
expectations, ethical issues (21) and the
impact of height gain on physical and psy-
chosocial well-being.(20)
Cianfarani S., et al.
J Clin Res Ped Endo 2009;1(3):105–115 109
Figure 1: Mean serum IGF-I SDS concentration between NFSS
(Non Familial Short Stature: height ≤-2 SDS and corrected tar-
get ≤-1.9 SDS), FSS ( Familial Short Stature: height ≤-2 SDS and
corrected target >-1.9 SDS) and control group (height >-2
SDS). Data are expressed in mean ± SEM. Personal unpub-
lished data. In the United States, the current FDA-
approved doses for GH in ISS are up to
0.30–0.37 mg/kg · wk.(22) The dose may be
increased if the growth response is consid-
ered inadequate, but there are no definitive
data concerning the long-term safety of
doses higher than 50 µg/kg/day(20), even if
the upper limit of GH dosage used in other
pediatric conditions is approximately 70
µg/kg/day.(23, 24) The evaluation of serum
IGF-I levels, together with auxological
parameters, is important to assess efficacy,
safety and compliance and to adjust the
dose, in particular in ISS patients in whom
potential GHI may be the cause of a poor
response to the standard dose. The correla-
tion between IGF-I levels in prepubertal GH-
naive children with ISS and change in height
SDS shows that higher growth response cor-
responds to lower baseline serum IGF-I lev-
els.(25, 26) IGF-I levels that are consistently
elevated (≥2.0 SDS) should prompt consider-
ation of GH dose reduction.(20)
A successful response to GH treatment in
the first year is defined by a delta height SDS
more than 0.3 to 0.5, a first year height
velocity increment more than 3 cm/year or a
height velocity SDS more than 1, because
height velocity in cm/yr depends on age and
is less reliable. To evaluate the long-term
response a number of parameters should be
taken into account:(20) a) adult height SDS;
b) height gain in SDS in comparison with the
height at start of therapy; c) difference
between adult height and predicted height;
d) difference between the adult height and
the target height.
GH treatment increases growth rate in the
first year, but there are controversies about
the effect on final height. It is difficult to
obtain homogeneous results about the effect
of treatment, because the ISS population is
widely heterogeneous. Moreover a wide vari-
ety of dosages have been prescribed in sev-
eral trials and most studies are uncontrolled.
A recent systematic review has evaluated the
short-term and long-term results of ten stud-
ies (seven of which were sponsored by or
received support from pharmaceutical com-
panies), published between 1989 and 2004,
that included 741 children with ISS, treated
with GH from 6 months to 6.2 years versus
placebo or no treatment. Only one study
reported adult height(27) and one reported
near final height.(28) Near final height of
treated girls was on average 7.5 cm higher
than untreated controls corresponding
approximately to 1.23 SDS.(28) Treated chil-
dren showed on average an adult height 3.7
cm (or 0.51 SDS) higher than placebo-treated
group.(27) These results are partially similar
to those reported in a previous meta-analy-
sis, that analyzed 10 controlled trials (some
of which considered also by the Cochrane
review) and 28 uncontrolled trials. In this
report the adult height achieved by GH-treat-
ed individuals exceeded that of untreated
controls by 0.78 to 0.84 SDS, equivalent to 5-
6 cm.(21) The National Cooperative Growth
Study (a large surveillance study of GH use
in the North America, in which 20% of all
children had ISS), showed an increment of
growth rate and height SDS during the first
year of treatment, followed by lesser degrees
of catch-up over the next 6 years.
Nevertheless, in the 7th year of therapy mean
growth rate of the children was greater than
the pretreatment value.(29)
Recently, a randomized controlled trial in
ISS children has investigated the effect on
growth up to the achievement of adult
height of two GH doses (33 or 67
µg/kg/day), demonstrating  that GH treat-
ment significantly increased the adult height
by approximately 1 SDS (approx. 6 cm) after
a mean duration of therapy of 5.9 ± 1.1
years, allowing them to attain a height close
to that of their parents. The GH effect was
dose-dependent and the children with par-
ents of normal heights responded best.(30)
In attempt to find  the predictive factors of
growth response to GH therapy to identify
the children that could benefit from GH ther-
apy, several multivariate models have been
proposed. The best growth response is found
in children with parents of normal height
Idiopathic Short Stature
© 2009 Journal of Turkish Pediatric Endocrinology and Diabetes Society 110(NFSS) compared with children from short
parents (FSS).(27, 30, 31) Bone age delay is
another important predictor,(27, 31) being
positively related to the response. The predic-
tion model of  Leschek et al.(27) explains
84% of the variation in height gain and indi-
cates that the best response is associated with
lower baseline height SDS relative to gender
adjusted midparental height SDS, lower pre-
treatment height velocity, lower baseline IGF-
I concentrations and greater bone age delay.
Nevertheless if the variables were considered
individually, only bone age delay was signif-
icantly correlated with the height gain.(27)
One of the aims of long-term GH treat-
ment is the improvement of quality of life,
but validated instruments to evaluate this
effect are not currently recommended as
part of routine care.(20) Short stature among
children with ISS enrolled in the only long-
term placebo-controlled study was not asso-
ciated with problems in psychological adap-
tation or self-concept with the psychological
instruments employed. GH treatment was
associated with a trend toward improvement
in problem behaviours, as measured by
questionnaires completed by study partici-
pants’ parents. It remains to be determined
whether GH treatment significantly impacts
adaptation, psychosocial function, or quality
of life in children with ISS.(32)
The possible side effects in GH-treated
children with ISS are similar to those previ-
ously reported in children receiving GH
therapy for other indications.(20)
Regular monitoring for scoliosis, tonsillar
hypertrophy, papilledema and slipped capital
femoral epiphysis should be performed as
part of the regular physical exam during fol-
low-up visits. Thus far, no instances of elevat-
ed blood glucose in GH-treated patients with
ISS have been reported, but monitoring of
glucose metabolism is strongly advised.
Increased risk of neoplasia or cancer
relapses has been associated with GH thera-
py. Large-scale epidemiological studies have
demonstrated a link between high concen-
trations of IGF-I and many of the common
cancers of adulthood, such as carcinomas of
prostate, lung, breast and colon.(33, 34, 35)
Overall, available data suggest that high lev-
els of IGF-I and low levels of IGF binding
protein-3 (IGFBP-3) are predictive of an
increased cancer risk. GH causes increased
serum IGF-I and to a lesser extent, IGFBP-3
and consequently increases the ratio of IGF-
I to IGFBP-3, thus raising concern on safety
of the long-term GH therapy.(36, 37, 38)
To date, no increased risk of malignancy
in ISS children undergoing GH treatment has
been reported. However, it should be recog-
nized, that the available pharmacovigilance
data is insufficient in several aspects: a) very
few long-term randomized controlled trials
have been conducted in ISS children so far;
b) registration trials of GH indications have
relied on limited number of patients, have
not included randomized control or placebo
groups (with a very small number of excep-
tions) and are not a reliable source of safety
data when dealing with rare events; c) most
of the available information has been
obtained from large post-marketing studies
organized by GH manufacturers and con-
ducted for too limited time. Indeed these
programs have efficiently identified health
issues occurring during the treatment (dia-
betes, slipped capital femoral epiphyses,
intracranial hypertension), but cannot
address health issues occurring after treat-
ment is discontinued; d) national pharma-
covigilance programs are poorly efficient to
detect rare events that would occur several
years after the discontinuation of GH treat-
ment and that are unlikely to be notified. 
More studies are needed to detect
whether children and young adults who
have been treated with GH are at increased
risk of cancer. 
The Role of GH Treatment
Alternatives
Androgens
In boys with CDGP, whose puberty and
bone age are substantially delayed, testos-
terone is the appropriate therapy.
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as a valid therapeutic approach in CDGP
children. Although it offers the advantage
of oral administration, the disadvantages
are the weak androgenic activity and the
remote risk of hepatotoxicity.
GnRH analogues
Therapy with GnRH analogues (GnRHa)
has been proposed to delay bone matura-
tion and pubertal development ultimately
leading to increased adult height.(39, 40)
Monotherapy with GnRHa in both sexes
has shown a small and variable effect on
adult height gain and the duration of treat-
ment seems to be positively correlated with
the gain in final height. However, due to the
lack of conclusive data, this treatment is not
recommended. Concerns have been raised
regarding potential adverse effects of GnRHa,
including on bone mineral density (41) and
on the psychological consequences of delay-
ing puberty.(42) Combination therapy with
GnRHa and GH might have potential value,
although convincing data are not yet avail-
able. 
AROMATASE INHIBITORS
Aromatase inhibition has been proposed
to stimulate growth in the presence of
androgens, whereas bone age advancement
is slowed due to inhibition of estrogen pro-
duction. An increase in predicted adult
height has been shown in males with
CDGP,(43) but adult height data are not
available. The use of aromatase inhibitors in
females is currently considered unsafe. To
date, the long-term efficacy and safety of
aromatase inhibitors in males with ISS has
not been demonstrated. 
Combination therapy with aromatase
inhibitors and GH has been reported to slow
down the tempo of bone age acceleration
and increase predicted adult height,(44)
however, long-term follow-up of these
patients is still required. 
In conclusion, aromatase inhibitors
might theoretically represent suitable thera-
peutic agents, alone or in combination with
GH, in boys with ISS. Evidence, however, is
still limited and this treatment should be
still considered only within controlled clin-
ical trials.
IGF-I
In the United States, Japan, and
Europe IGF-I has been approved for treat-
ment of non-GH deficient children with
severe IGF-I deficiency.(45) Therefore,
IGF-I therapy might be theoretically con-
sidered in those ISS children who do not
respond to GH and have low IGF-I con-
centrations. However, the finding of sub-
normal IGF-I levels in ISS children is
exceptional. In subjects with IGF-I in the
low normal range there is no controlled
study comparing the effect of the therapy
with GH or GH treatment alternatives with
IGF-I administration.
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